VivoSeq
Cardiovascular

Aortic Stenosis

50

Pipeline Programs↗

20

Active Trials↗

24

Companies Involved↗

Aortic Stenosis is a moderately active landscape with 50 programs across 24 companies. The most active players are Amgen, GSK, Bristol-Myers Squibb. 20 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

30/100

Mech. Concentration

11/100

Completion Rate

67/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3AbbVie logo

AbbVie

1 program

ApprovedOrion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

45 of 48 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody12%Peptide12%RNA therapy12%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 94% of 54 pipeline programs.

Analysis

Trial Status

54

clinical trials

Completed14 · 26%
Unknown status13 · 24%
Recruiting12 · 22%
Terminated5 · 9%
Active, not recruiting4 · 7%
Not yet recruiting4 · 7%
Other2 · 4%

Clinical Trials

Trial Activity

54 trials

Identifying Biological Markers of Cardiovascular Events in Patients With Aortic Stenosis or TAVI
Recruiting·HHospices Civils de Lyon·N/A·NCT06713889·125 enrolled
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Recruiting·RREDNVIA Co., Ltd.·Phase 2/3·NCT05143177·580 enrolled
A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
Recruiting·RRenJi Hospital·N/A·NCT07335900·25 enrolled
Angiotensin Receptor Blockers in Aortic Stenosis
Recruiting·IInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval·Phase 4·NCT04913870·144 enrolled
VISTA Nova Study (Navitor Post-Market Clinical Follow Up Study)
Recruiting·AAbbott Medical Devices·N/A·NCT06008080·1,000 enrolled
Optimized Expansion of the Implanted Transcatheter Aortic Valve to Reduce Hypoattenuating Leaflet Thickening in Non-atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Implantation: an International, Multicentre, Randomized Controlled Trial
Recruiting·—·Preclinical·NCT07042529·1,010 enrolled
A Prospective Randomized Trial Assessing the Safety and Effectiveness of the DurAVR® Biomimetic Valve Designed for Physiologic Flow Compared to Commercial TAVR Devices
Recruiting·AAnteris Technologies Ltd.·Preclinical·NCT07194265·1,650 enrolled
PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI
Recruiting·PPortuguese Association of Interventional Cardiology·N/A·NCT07343674·500 enrolled
Aspirin Versus Clopidogrel for Leaflet Thrombosis Prevention in Patients Undergoing Transcatheter Aortic Valve Replacement: ACLO-TAVR Trial
Recruiting·YYonsei University·Preclinical·NCT05493657·270 enrolled
Evaluation of Immunologic and Image Morphologic Parameters to Predict Disease Progression in Patients With Moderate Aortic Valve Stenosis
Recruiting·HHeinrich-Heine University, Duesseldorf·N/A·NCT05851209·938 enrolled
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
Recruiting·Novartis logoNovartis·Phase 2·NCT05646381·502 enrolled
Determining Clinical and Cardiopulmonary Exercise Testing Parameters That Predict Improvement in Functional Capacity and Complications After Transcatheter Aortic Valve Implantation
Recruiting·HHospital Clinic of Barcelona·N/A·NCT06833762·161 enrolled
Colchicine and Inflammation in Aortic Stenosis
Active, not recruiting·RRadboud University Medical Center·Phase 3·NCT05162742·150 enrolled
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: First In Human Study (EMBARK Study)
Active, not recruiting·AAnteris Technologies Ltd.·Preclinical·NCT05182307·150 enrolled
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
Active, not recruiting·AAnteris Technologies Ltd.·Preclinical·NCT05712161·15 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)